Welcome To GMJ Technologies!

We are an emerging leader in novel analytical technologies for protein characterization. With robust fluidic and detection mechanisms, GMJ Technologies is developing novel capillary electrophoresis (CE) systems for efficient characterizations of biomolecules. Our pioneering technologies employ next generation capillary electrophoresis with UV detection, Laser-Induced Fluorescence (LIF) detection, and/or mass spectrometry (MS) to enable powerful applications in biopharmaceutical and biomedical protein characterization. Efficient protein analytics is critical to better biopharmaceutical product understanding and successful regulatory filing. Capillary electrophoresis offers several potentials but existing technologies are cumbersome and less easy-to-use.  Our technology is advance but robust and easy-to-use, offering several capabilities that increase productivity in protein characterization.


Technology Pipeline

CE-MS Auxiliary ESI Delivery Module CE-UV/LIF
  • Robust CE-MS solution for impurity and product characterization.
  • Permits UV-MS and LIF-MS acquisition
  • Analysis with sub-micron sample volume
  • Electrospray ionization for SEC or SCX
  • Coupling icIEF with mass spectrometry
  • Compatibility with multiple MS system
Robust ultra-sensitive CE-LIF solution for fluorescently labeled samples whether at process, characterization, or quality control stage


Our Team

Tosin Dada, PhD (Principal/CEO)

Dr Tosin Dada is the lead principal and CEO of GMJ Technologies. He has over 10 years of exposure in analytical instrument development and applications in bioanalysis. He brings diverse experience in separation, spectroscopy, optics, mass spectrometry, fluidics,, biopharmaceutical analytical development, and entrepreneurship. He is a leader in development of capillary electrophoresis techniques with notable contributions.

David Latta (Advisor, Business Development)

David brings over 35 years of experience in research and business development to GMJ Technologies. Some of David’s highlights are as follows:

  • 12 years in research creating one US patent and several publications. The patent was executed from lab to pilot to full scale production operation and licensed to key manufacturers throughout the world.
  • Deep experience in business development and teaming arrangements involving design, procure and construction of large complex work in highly specialized projects.
  • Proven leadership capabilities in a very tightly scheduled construction, delivery and startup of complex projects averaging up to $3-4 billion.
  • Team lead in refining and modifying of mining and processing container glass facility moving from red to black, creating a highly successful operation.
  • Co-founder of a consulting engineering group with from 5 to 45 employees.


GMJ Technologies Awarded Competitive Grant from the National Science Foundation (NSF)

GMJ Technologies has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to conduct research and development (R&D) work on Next Generation Capillary Electrophoresis with Mass Spectrometry. Emergence of complex protein-therapeutic modalities and biosimilar with increasing regulatory requirements for deep characterization of biologics is creating the need for efficient protein characterization tool in Bio-Pharma. Similarly, complexity of proteins in biological matrices such as serum, tissues, and cell is creating unmet needs in biomedical research and development. Capillary electrophoresis with mass spectrometry is a power analytical tool with great potential for protein analysis.

GMJ Technologies is proud to be among the winners of NSF SBIR Phase I award, which makes the company eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales. This awards will provide great opportunity to develop an efficient CE-MS system that improves efficiency and productivity of researchers in biopharmaceutical and biomedical research


Please Contact Us for more information about our company and technologies. You can also reach us at 4000 Mason Road, Seattle, WA 98195. Telephone: (206)-497-1337